Q3 EPS Estimates for Pelthos Therapeutics Lowered by Analyst

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Pelthos Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($4.60) per share for the quarter, down from their prior estimate of ($3.27). The consensus estimate for Pelthos Therapeutics’ current full-year earnings is ($13.25) per share. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q4 2026 earnings at ($4.71) EPS, FY2027 earnings at ($7.76) EPS, FY2028 earnings at $3.16 EPS, FY2029 earnings at $7.22 EPS and FY2030 earnings at $10.23 EPS.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. The business had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.

Separately, Oppenheimer cut their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Pelthos Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.40.

Pelthos Therapeutics Stock Performance

Shares of PTHS stock opened at $25.90 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a 52-week low of $18.19 and a 52-week high of $37.50. The business has a 50-day simple moving average of $27.48 and a 200-day simple moving average of $25.14. The stock has a market cap of $99.20 million, a PE ratio of -1.18 and a beta of 3.10.

Hedge Funds Weigh In On Pelthos Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in Pelthos Therapeutics in the 4th quarter valued at about $343,000. Geode Capital Management LLC increased its stake in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $1,085,000. Ikarian Capital LLC lifted its position in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares in the last quarter. Finally, Boothbay Fund Management LLC boosted its stake in shares of Pelthos Therapeutics by 279.8% in the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. 77.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pelthos Therapeutics

In other Pelthos Therapeutics news, Director Todd C. Davis bought 35,948 shares of Pelthos Therapeutics stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director directly owned 75,834 shares in the company, valued at $2,109,701.88. This represents a 90.13% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 1,638 shares of company stock valued at $43,107 in the last three months. 12.70% of the stock is owned by insiders.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).